Annual Report

Overview

The report highlights LLS's 2022 support for 14 newly FDA-approved blood cancer treatment options and the launch of the PedAL Master Clinical Trial. It reports more than $385 million in financial-assistance awards to more than 75,000 patients. The organization raised $444 million and spent $434 million, or 81% of expenses, on programs supporting research, patients, advocacy, and care.

Document

Report type: Annual Report
Class: Financial
Scope: Full report
Fiscal year: 2022
Period: Ends 30 June 2022
Language: English
Pages
File size

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services